CURRICULUM VITAE OREGON HEALTH & SCIENCE UNIVERSITY

NAME	Erick H.	Turner.	M.D.
------	----------	---------	------

DATE 9/23/2012

PRESENT POSITION AND ADDRESS

Academic Rank:	 Associate Professor Associate Professor (Joint) Senior Scholar
Department/Divisi on:	 Psychiatry Pharmacology & Physiology Center for Ethics in Health Care
Professional Address:	3710 SW US Veterans Hospital Road, P3MHDC Portland, OR 97239
E-Mail Address:	<u>turnere@ohsu.edu</u> <u>erick.turner@va.gov</u>

II. EDUCATION

Undergraduate and Graduate

9/85 - 6/89	MD, Oregon Health Sciences University, Portland, OR	
9/82 - 5/85	BS in Science, Portland State University, Portland OR	
9/75 - 6/77	Swedish Language Courses, University of Stockholm,	
Sweden		
6/72 - 8/72	Foreign Study through Rollins College, Winter Park, FL	
Madrid, Spain		
1/74 - 6/74	Foreign Study while at Duke, University of the Andes,	
Bogotá, Colombia		
9/71 - 5/75	BA in Spanish and Psychology, Duke University, Durham,	
NC		

Postgraduate:

National Institute of Mental Health (NIMH): Staff Fellow, Clinical Psychobiology Branch, Bethesda, Maryland, 7/92 – 4/98 (first year, ending June 1993, served as 4th and final year of psychiatry residency) University of California: Irvine Medical Center, Orange, CA, Psychiatry resident, 7/89-6/92 (3 years—credit for 4th year of residency received with 1st year at NIMH—see below)

Certification:

American Board of Psychiatry & Neurology, certificate #42707 Initial certification April 30, 1996 – December 31, 2006 Recertified February 6, 2012; valid until 2022

Licenses:

MarylandActiveExpires: September 30, 2015 #D44211DEA # FT1330911 - Expires: 11-30-2014CaliforniaInactiveCaliforniaInactiveExpired: December 31, 1993 #G069708Controlled & Dangerous Substances #M35297; Expired: June 30, 2001

III. PROFESSIONAL EXPERIENCE

Academic:

Department of Psychiatry, 5/2001–present, Associate Professor (promoted from Asst. June 2013)

Department of Pharmacology & Physiology, 4/2001 - present – Joint Associate Professor

Center for Ethics in Health Care, OHSU – Senior Scholar, 7/2008 – present

NIMH Staff Fellow 1992-1998 (also listed above under Postgraduate Education)

Administrative:

1998 – 2001: Medical Officer (Clinical Reviewer), Psychotropics Team, Division of Neuropharmacologic Drug Products (DNDP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Rockville, MD

Other:

2001 – Present: Staff Psychiatrist, Portland VAMC, Portland, OR Private practice (solo) – psychopharmacology

Dates 9/94 –3/01 (closed practice upon move to Portland, OR) 5415 W. Cedar Lane, Suite 201-B Bethesda, Maryland 20814 (301) 718-9305

Contemporary Psychiatric Services (group practice)

5920 Hubbard Drive, Rockville, MD 20852

12/93 - 8/94 (left group practice to set up solo practice)

Outpatient and inpatient psychiatry as independent contractor

Inpatient coverage at Charter Behavioral Health Systems at Potomac Ridge, Rockville, MD Hopkins Bayview Med Ctr; Highland Health Facility Baltimore, Maryland On-call weekend coverage for emergency room psychiatric evaluations, admissions, and for psychiatric wards One 24-hour shift per month 7/93 - 8/94 Clinica Nueva Esperanza Spanish-speaking mental health clinic subsidized by county Medication management; some psychotherapy (in Spanish) 431 S. Bristol Street, Santa Ana, California 92703 Director: (b) (6) 9/91 - 6/92 (left California for NIMH position) Lakeview Medical Group Medication management provided on-site to clients of "board-andcare" homes Patient population: chronically mentally ill, developmentally disabled 928 Town & Country Office Park, Orange, California 92668 Coordinator/group manager: (b) (6) 10/90 - 6/92 Past hospital affiliations NIH Clinical Center, Bethesda, MD, 7/92 - 3/98 Suburban Hospital, Bethesda, MD, 8/94 - 9/99Charter Behavioral Health Systems at Potomac Ridge (formerly Treatment Center), Rockville, MD, 1/94 - 1999 Potomac Ridge Hopkins Bayview Medical Center (formerly Francis Scott Key Baltimore, MD, 7/93 – approx. 1994 Medical Center), Highland Health Facility, Baltimore, MD, 7/93 – approx. 1994

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest:

Current: Publication bias, esp. using FDA Drug Approval Packages as a registry and results database to document existence of unpublished and "spun" clinical trials

Previous: Clinical trials issues, FDA matters, placebo (esp. scientific need for), drug development process, interferon-induced depression, use of 5-hydroxytryptophan (serotonin precursor) in treatment of depression, mood disorders, seasonal affective disorder (SAD), circadian rhythms.

Grants and Contracts:

Federal:

Scientific Resource Center II to Support AHRQ Effective Health Care Program: *Reporting Bias in Systematic Reviews and Metaanalyses*; Agency for Healthcare Research and Quality, HHSA 290 2012 00004; Co-Investigator (PI: Mark Helfand, MD, MPH, MS). FTE 25%.

VA Cooperative Study (CSP590) of the use of lithium to prevent suicide in patients with a recent suicide attempt. Site PI for Portland VA Medical Center. Recruitment to begin March 2015. FTE 15%.

Standard Care Pathway of STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder); multicenter clinical trial sponsored by NIMH; site subinvestigator at Portland VA Medical Center, 1/02 – 2007; site PI Peter Hauser, M.D.; study PI Gary Sachs, M.D.; 40% effort.

Randomized Acute Depression Pathway of STEP-BD; phase 4 placebo-controlled clinical trial of bipolar depression; subinvestigator; Portland VA Medical Center, 10/02 – 2006; site PI

Peter Hauser, M.D.; study PI Gary Sachs, M.D.;10% effort. (Previous intramural NIMH support listed below)

State and Local:

Oregon Medical Research Foundation,^{(b) (4)} awarded fall 2003, 5-Hydroxytrytophan (5-HTP) Augmentation of SSRI Therapy in Patients with Interferon-Induced Depression; PI. (Study not approved by IRB due to concerns re purity of dietary supplement; funds returned)


Other Support:

University of Groningen, March 19, 2012 – February 1, 2013; 12,000 Euros (~\$15,000), for mentoring junior researcher on project on publication bias in clinical trials on anxiety disorders; PI

is ^{(b) (6)}, professor of psychiatry at that university's; 5% effort.

Stanley Medical Research Foundation, March 2008 – March 2010; 30% effort; study PI; Resulted in publication "Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database"

Pharmaceutical company support:



<u>Intramural NIH support (during NIMH fellowship)</u> <u>As PI (all approx. 50% effort)</u>

A positron emission tomographic (PET) study of the acute effects of bright artificial light in patients with seasonal affective disorder and healthy volunteers. Subinvestigator. Study conducted at NIMH. 1996-97.

A double-blind placebo-controlled study of singledose metergoline in depressed seasonal affective disorder patients. Principal Investigator (PI). Study conducted at National Institute of Mental Health (NIMH). 1994-95.

Single-case trial of bright artificial light in the treatment of seasonal hot flashes. Principal investigator. NIMH. 1992-93.

As co-investigator (all approx. 20% effort)

Tryptophan depletion vs catecholamine depletion vs sham depletion in patients with seasonal affective disorder in remission with light therapy. Subinvestigator. Study conducted at National Institute of Mental Health (NIMH).1996-97. A positron emission tomography (PET) study of the effect of m-CPP on brain metabolism in SAD patients versus controls. Principal Investigator. Study conducted at NIMH. 1995-96. Open-label trial of extended bed rest and darkness as a mood stabilizer in a patient with rapid-cycling bipolar disorder. Subinvestigator. NIMH. 1995-96. Crossover treatment trial of light visor vs. light box treatment in patients with seasonal affective disorder. Subinvestigator. NIMH. 1995-96. Double-blind placebo-controlled clinical trial of exogenous melatonin administration and withdrawal in patients with rapid-cycling bipolar disorder. Subinvestigator, NIMH, 1994-95. Double-blind placebo-controlled single-dose study of ipsapirone in patients with seasonal affective disorder. Subinvestigator. NIMH. 1993-94. Double-blind placebo-controlled trial of leuprolide (Lupron[®]) with and without testosterone replacement. Subinvestigator. NIMH. 1994-96. Open-label trial of bright artificial light in bipolar depression. Subinvestigator. NIMH. 1993-94. Double-blind placebo-controlled trial of cvanocobalamin (vitamin B12) in the treatment of seasonal affective disorder. Subinvestigator. NIMH. 1992-93.

Pending Support:

Ph.D.

Publications/Creative Work:

Peer-reviewed journal articles (reverse chronological order):

1. Cuijpers, P., **Turner**, E. H., Koole, S. L., van Dijke, A., & Smit, F. (2014a). What is the threshold for a clinically relevant effect? The case of major depressive disorders. Depression and Anxiety, 31(5), 374–378. doi:10.1002/da.22249

2. Cuijpers, P., **Turner**, E. H., Mohr, D. C., Hofmann, S. G., Andersson, G., Berking, M., & Coyne, J. (2014b). Comparison of psychotherapies for adult depression to pill placebo control groups: a meta-analysis. Psychological Medicine, 44(4), 685–695. doi:10.1017/S0033291713000457

3. **Turner** EH (2013) How to access and process FDA drug approval packages for use in research. *BMJ* 2013;347:f5992

4. **Turner** EH (2013) Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs 27: 457–468. doi:10.1007/s40263-013-0067-9.

5. Roseman M, **Turner** EH, Lexchin J, Coyne JC, Bero LA, et al. (2012) Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ 345: e5155.

6. **Turner** EH, Knoepflmacher D, Shapley L (2012) Publication Bias in Antipsychotic Trials: An Analysis of Efficacy Comparing the Published Literature to the US Food and Drug Administration Database. PLoS Med 9: e1001189. Available: <u>http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2F</u> journal.pmed.1001189

7. Thombs BD, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, **Turner EH**, and Ziegelstein RC. Rethinking recommendations for screening for depression in primary care. CMAJ. March 6, 2012 184:413-418.

8. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, **Turner EH**, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA: The Journal of the American Medical Association (2011) vol. 305 (10) pp. 1008-17

9. Moreno SG, Sutton AJ, **Turner EH**, Abrams KR, Cooper NJ, Palmer TM, Ades AE. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ. 2009 Aug 7;339:b2981. doi: 10.1136/bmj.b2981.

10. **Turner EH**, Matthews A, Linardatos E, Tell RA,

Rosenthal R. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. N Engl J Med. 2008 Jan;358(3):252-60.

11. **Turner EH**, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-

hydroxytryptophan. Pharmacol Ther. 2006 Mar;109(3):325-38. Epub 2005 Jul 14. Review.

12. **Turner EH**. A Taxpayer-Funded Clinical Trials Registry and Results Database. PLoS Med. 2004 Dec;1(3):e60.

13. **Turner EH**, Blackwell AD. 5-hydroxytryptophan plus SSRIs for interferon-induced depression: Synergistic mechanisms for normalizing synaptic serotonin. Medical Hypotheses, Volume 65, Issue 1, 2005, Pages 138-144.

14. **Turner EH**, Schwartz P, Lowe C, et al. A Double-Blind Placebo-Controlled Study of Single-Dose Metergoline in Depressed Seasonal Affective Disorder Patients. Journal of Clinical Psychopharmacology. 2002 Apr;22(2):216-20.

15. Postolache TT, Wehr TA, Doty RL, Sher L, **Turner EH**, Bartko JJ, Rosenthal NE. Patients with seasonal affective disorder have lower odor detection thresholds than control subjects. Arch Gen Psychiatry. 2002 Dec;59(12):1119-22.

16. **Turner EH**, Leibenluft E, Albert P, Wehr T, Rosenthal N. Effect of season and light treatment upon hot flashes in a perimenopausal SAD patient. Chronobiology International. 1995;12:290-297.

17. Dobscha, SK, Winterbottom L, Hoffman WE, **Turner EH**, et. al: Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center. Psychiatr Serv. 2003 Feb;54(2):195-200.

18. Sher L, Matthews JR, **Turner EH**, Postolache TT, Katz KS, Rosenthal NE: Early response to light therapy partially predicts long-term antidepressant effects in patients with seasonal affective disorder. J Psychiatry Neurosci 2001; 26(4): 336-8.

19. Wehr TA, Duncan WC, Jr., Sher L, Aeschbach D, Schwartz PJ, **Turner EH**, Postolache TT, Rosenthal NEet al.: A circadian signal of change of season in patients with seasonal affective disorder. Arch Gen Psychiatry 2001; 58(12): 1108-14.

20. Schwartz PJ, Rosenthal NE, Kajimura N, Han L, **Turner EH**, Bender C, Wehr TA. Ultradian oscillations in cranial thermoregulation and electroencephalographic slow-wave activity during sleep are abnormal in humans with annual winter depression. Brain Res. 2000;866:152-67.

21. Schwartz PJ, **Turner EH**, Garcia-Borreguero D, et al. Serotonin hypothesis of winter depression: behavioral and

neuroendocrine effects of the 5-HT(1A) receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects. Psychiatry Res. 1999;86:9-28.

22. Postolache TT, Doty RL, Wehr TA, Jimma LA, Han L, **Turner EH**, et al. Monorhinal odor identification and depression scores in patients with seasonal affective disorder. J Affect Disord. 1999;56:27-35.

23. Neuhaus IM, Schwartz PJ, **Turner EH**, et al. Gender differences in glycosylated hemoglobin levels in seasonal affective disorder patients and controls. Compr Psychiatry. 1999; 40:234-7.

24. Wehr TA, **Turner EH**, Shimada JM, Lowe CH, Barker C, Leibenluft E. Treatment of rapidly cycling bipolar patient by using extended bed rest and darkness to stabilize the timing and duration of sleep. Biol Psychiatry. 1998;43:822-8.

25. Rosenthal NE, Mazzanti CM, Barnett RL, Hardin TA, **Turner EH**, Lam GK, Ozaki N, Goldman D. Role of serotonin transporter promoter repeat length polymorphism (5- HTTLPR) in seasonality and seasonal affective disorder. Mol Psychiatry. 1998;3:175-7.

26. Postolache TT, Hardin TA, Myers FS, **Turner EH**, Yi LY, Barnett RL, Matthews JR, Rosenthal NE. Greater improvement in summer than with light treatment in winter in patients with seasonal affective disorder. Am J Psychiatry. 1998;155:1614-6.

27. Neumeister A, **Turner EH**, Matthews JR, et al. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry. 1998;55:524-30.

28. Feldman-Naim S, Lowe CH, Myers FS, **Turner EH**, Weinstock LM, Leibenluft E. Validation of the hypomania interview guide-seasonal affective disorder (HIGH-SAD) version in patients with rapid cycling bipolar disorder. Depress Anxiety. 1998;8:166-8.

29. Schwartz PJ, Rosenthal NE, **Turner EH**, Drake CL, Liberty V, Wehr TA. Seasonal variation in core temperature regulation during sleep in patients with winter seasonal affective disorder. Biol Psychiatry. 1997;42:122-31.

30. Schwartz PJ, Loe JA, Bash CN, Bove K, **Turner EH**, Frank JA, Wehr TA, Rosenthal NE. Seasonality and pituitary volume. Psychiatry Res. 1997;74:151-7.

31. Leibenluft E, Schmidt PJ, **Turner EH**, et al. Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men. J Clin Endocrinol Metab. 1997;82:3203-7.

32. Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA,

Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder [see comments]. J Clin Psychiatry. 1997;58:383-8.

33. Feldman-Naim S, **Turner EH**, Leibenluft E. Diurnal variation in the direction of mood switches in patients with rapid-cycling bipolar disorder. J Clin Psychiatry. 1997;58:79-84.

34. Feldman-Naim S, Myers FS, Clark CH, **Turner EH**, Leibenluft E. Agreement between face-to-face and telephoneadministered mood ratings in patients with rapid cycling bipolar disorder. Psychiatry Res.1997;71:129-32.

35. Ozaki N, Rosenthal NE, Pesonen U, Lappalainen J, Feldman-Naim S, Schwartz PJ, **Turner EH**, Goldman D. Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biol Psychiatry. 1996;40:1267-72.

36. Leibenluft E, Feldman-Naim S, **Turner EH**, Schwartz PJ, Wehr TA. Salivary and plasma measures of dim light melatonin onset (DLMO) in patients with rapid cycling bipolar disorder. Biol Psychiatry. 1996;40:731-5.

37. Drake CL, Schwartz PJ, Turner EH, Rosenthal NE.
Cognitive performance in seasonal affective disorder: pattern recognition and the Stroop task. J Nerv Ment Dis. 1996;184:56-9.
38. Wehr TA, Schwartz PJ, Turner EH, Feldman-Naim S, Drake CL, Rosenthal NE. Bimodal patterns of human melatonin secretion consistent with a two-oscillator model of regulation. Neurosci Lett. 1995;194:105-8.

39. Wehr TA, Giesen HA, Moul DE, **Turner EH**, Schwartz PJ. Suppression of men's responses to seasonal changes in day length by modern artificial lighting. Am J Physiol. 1995;269:R173-8.

40. Swedo SE, Pleeter JD, Richter DM, Hoffman CL, Allen AJ, Hamburger SD, **Turner EH**, et al. Rates of seasonal affective disorder in children and adolescents. Am J Psychiatry. 1995;152:1016-9.

41. Leibenluft E, **Turner EH**, Feldman-Naim S, Schwartz PJ, Wehr TA, Rosenthal NE. Light therapy in patients with rapid cycling bipolar disorder: preliminary results. Psychopharmacol Bull. 1995;31:705-10.

42. Ozaki N, Rosenthal NE, Mazzola P, Chiueh CC, Hardin T, Garcia-Borreguero D, Schwartz PJ, **Turner E**, et al. Platelet [3H]paroxetine binding, 5-HT-stimulated Ca2+ response, and 5-HT content in winter seasonal affective disorder. Biol Psychiatry. 1994;36:458-66.

43. Oren DA, Teicher MH, Schwartz PJ, Glod C, **Turner EH**, et al. A controlled trial of cyanocobalamin (vitamin B12) in the

treatment of winter seasonal affective disorder. J Affect Disord. 1994;32:197-200.

44. Hoffman WF, Ballard L, **Turner EH**, Casey DE. Threeyear follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biol Psychiatry. 1991 Nov 1;30(9):913-26.

Non-peer-reviewed (reverse chronological): Invited Articles

Turner EH, Rosenthal R. Efficacy of antidepressants. Bmj. Mar 8 2008;336(7643):516-517. Turner EH, Tramèr MR, et al. Debate: It Can Be Unethical Not to Use Placebo. Public Library of Science Medicine. "Second" half of debate; both halves indexed together as: Stang A, Hense H, Jöckel K, Turner EH, Tramèr MR (2005) Is It Always Unethical to Use a Placebo in a Clinical Trial? PLoS Med 2(3): e72. Available at:http://medicine.plosjournals.org/perlserv/?request=getdocument&doi=10.1371/journal.pmed.0020072

Letters to the editor

1. **Turner EH** (2013) Author's Reply to Shrier: "Publication Bias, With a Focus on Psychiatry: Causes and Solutions." CNS Drugs. doi:10.1007/s40263-013-0099-1.

2. **Turner EH** (2011) The effect of funding source on outcome reporting among drug trials. Ann Intern Med 154: 137; author reply 138.

3. **Turner EH** (2010) All the relevant data? BMJ 341: c6487.

4. Loftis JM, **Turner EH**. Novel treatment strategies for depression in patients with hepatitis C. Psychosomatics 2010;51:357-8.

5. **Turner E**, Moreno SG, Sutton AJ (2009) Ranking antidepressants. Lancet 373: 1760; author reply 1761-1762.

6. **Turner EH**, Moaleji NJ, Arnold BL. Closing a Loophole in the FDA Amendments Act. Science. Oct 3 2008; 322(5898):44-46.

7. **Turner EH**. Posting FDA new drug application reviews. JAMA. Aug 22 2007;298(8):863-864.

8. **Turner E**, Tramèr M (2005) Authors' Reply. PLoS Med 2(6): e187. Available at:

http://medicine.plosjournals.org/perlserv/?request=getdocument&doi=10.1371/journal.pmed.0020187

9. **Turner E**. Correction/clarification about FDA

review documents. PLoS Med. 2005 Dec;2(12):e422; author reply e423. Epub 2005 Dec 27.

10. Oren DA, Schwartz PJ, **Turner EH**, Rosenthal NE, Wehr TA. Olfactory function in winter seasonal affective disorder [letter]. Am J Psychiatry. 1995;152:1531-2.

 Oren DA, Turner EH, Wehr TA. Abnormal circadian rhythms of plasma melatonin and body temperature in the delayed sleep phase syndrome [letter; comment]. J Neurol Neurosurg Psychiatry. 1995;58:379.
 Clark C, Schocket LS, Turner EH, Rosenthal NE. Light visor maintenance of light box response [letter]. Am J Psychiatry. 1997;154:1172.

Books

No books or book chapters have been authored. However, Google Books search indicates that first-authored article in NEJM (2008) has been cited in 440 books as of September 2012.

Reviews (also listed under peer-reviewed articles)

1. **Turner EH** (2013) Publication bias, with a focus on psychiatry: causes and solutions. CNS Drugs 27: 457–468. doi:10.1007/s40263-013-0067-9.

2. Thombs BD, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, **Turner EH**, and Ziegelstein RC. Rethinking recommendations for screening for depression in primary care. CMAJ. March 6, 2012 184:413-418.

3. Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, **Turner EH**, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA: The Journal of the American Medical Association (2011) vol. 305 (10) pp. 1008-17

4. Moreno SG, Sutton AJ, **Turner EH**, Abrams KR, Cooper NJ, Palmer TM, Ades AE. Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications. BMJ. 2009 Aug 7;339:b2981. doi: 10.1136/bmj.b2981.

5. **Turner EH**, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-

hydroxytryptophan. Pharmacol Ther. 2006 Mar;109(3):325-38. Epub 2005 Jul 14. Review. (also listed under header for peerreviewed articles)

Abstracts (reverse chronological):

<u>1st authored abstracts</u>

1. Peer Review Congress, Vancouver, BC, September

2009. Poster: Multiple Publication of Positive vs. Negative Trial Results in Review Articles: Influence on Apparent "Weight of the Evidence"

2. Turner EH, Matthews A, Linardatos E. Selective publication of antidepressant clinical trials. New Clinical Drug Evaluation Unit (NCDEU), 46th Annual Meeting, Poster II-78, Boca Raton, FL. June 14, 2006. (Early version of paper published in 2008, also given as invited talk at same conference in 2008.)

3. Society for Clinical Trials, Orlando, FL, May 22, 2006; Session IC: Trial Conduct and Reporting; talk title: "Documentation of Publication Bias in Industry-Sponsored Clinical Trials of Antidepressants". (Pre-submission version of study later published in NEJM.)

4. Turner EH, et. al. Motor Activity as a Measure of Severity of Mood Disorders, New Clinical Drug Evaluation Unit (NCDEU), Poster II-043, Boca Raton, FL, 6/2002.

5. Turner EH, Matthews J, Feldman-Naim S, et al. Effect of m-CPP on brain metabolism in SAD patients and controls. . Light Treatment and Biological Rhythms. Vancouver, British Columbia; 1997:8.

6. Turner EH, Schwartz P, Clark C, Myers F, Rosenthal N. Metergoline's effect on SAD symptoms. . Light Treatment and Biological Rhythms. Bethesda, MD; 1996:3.

7. Turner E, Leibenluft E, Wehr T, Rosenthal N. Seasonal hot flushes responsive to morning light therapy in a perimenopausal SAD patient. . Light Treatment and Biological Rhythms. San Diego, CA; 1993:49.

8. Turner EH, Buchsbaum M, Haier R. Thalamic structure and function in younger schizophrenics. Student Research Forum, Oregon Health Sciences University. Portland, OR; 1988.

9. Turner E, Hoffman W, Casey D. Neuroanatomical correlates of drug-induced parkinsonism in schizophrenics. Student Research Forum, Oregon Health Sciences University. Portland, OR; 1987.

Non-first-authored abstracts

 Matthews J, Turner E, Postolache T, et al. Acute effects of light therapy on cerebral blood flow in SAD patients and matched controls. Light Treatment and Biological Rhythms. Vancouver, British Columbia; 1997:7.
 Neumeister A, Turner E, Matthews J, et al. Reversal of antidepressant effects of light therapy by tryptophan and catecholamine depletion in SAD patients. Light Treatment and Biological Rhythms. Vancouver, British Columbia; 1997:6.

12. Leibenluft E, **Turner E**, Feldman-Naim S, Rosenthal N, Wehr T. Circadian rhythms and rapid cycling. American Psychiatric Association. New York; 1996:Talk #3E.

13. Clark C, Schocket L, **Turner E**, Ashman S, Rosenthal N. Efficacy of the light visor in maintaining antidepressant response in SAD patients. Light Treatment and Biological Rhythms. Bethesda, MD; 1996:19.

14. Neuhaus I, Schwartz P, **Turner E**, Feldman-Naim S, Matthews J, Rosenthal N. A comparison of winter glycosylated hemoglobin levels in SAD patients and controls. Light Treatment and Biological Rhythms. Bethesda, MD; 1996:31.

15. Feldman-Naim S, Leibenluft E, **Turner E**. Circadian variation in the direction of mood switches in patients with rapid cycling bipolar disorder. Light Treatment and Biological Rhythms. Bethesda, MD; 1996:6.

16. Garcia-Borreguero D, **Turner E**, Schwartz P, et al. Behavioral effects of the serotonergic 5-HT-1a receptor agonist ipsapirone in patients with seasonal affective disorder. Light Treatment and Biological Rhythms. Bethesda, MD; 1994:11.

17. Ozaki N, Rosenthal N, Garcia-Borreguero D, et al. Studies of platelet serotonergic systems in winter seasonal affective disorder. Light Treatment and Biological Rhythms. San Diego, CA; 1993:44.

18. Hoffman W, Ballard L, **Turner E**, Casey D. Three year follow-up of older schizophrenics: extrapyramidal syndromes, psychiatric symptoms, and ventricular brain ratio. Biological Psychiatry. 1991;30:913-926.

Hoffman W, Hansen T, Turner E, Casey D.
 Correlation of ventricular brain ratio with drug-induced parkinsonism and tardive dyskinesia in hospitalized schizophrenics. Biological Psychiatry. Chicago; 1987:267.
 Hoffman W, Labs S, Turner E, Casey D. Organic correlates of drug-induced parkinsonism. American Psychiatric Association. Chicago; 1987:51.

21. Hoffman W, Labs S, **Turner E**, Casey D. Tardive Dyskinesia and drug-induced parkinsonism: relationship to cerebral ventricular enlargement. Collegium Internationale Neuro-Psychopharmacologicum (CINP). San Juan, PR; 1986.

Invited Lectures, Conference Presentations or Professorships:

International (some items involve 2 or more talks at one location)

1. Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland, June 8, 2011, 2 talks—1 lecture + 1 roundtable discussion on topics of publication bias and transparency of drug regulatory agencies

2. McGill University, Montreal, Canada, 2 talks on publication bias and efficacy of antidepressants, 1 at Jewish General Hospital, 1 at Centre of Genomics and Policy, April 13, 2011

3. University of British Columbia, Vancouver, BC, Canada, 4 talks to different audiences regarding publication bias and efficacy of antidepressants, March 2-3, 2011

4. Danish University Antidepressant Group, keynote talk: The Earth is Flat, d < 0.5: The Silly Debate About Antidepressant Efficacy, November 5, 2010, Holckenhavn Castle, Nyborg, Denmark

5. Canadian Institutes of Health Research: Evidence-Based Perspectives on Detection and Clinical Care of Depression: Critique and Conversation. Montreal, Quebec, Canada. October 2009

6. Danish Society for Psychiatric Epidemiology, Copenhagen, Denmark. Annual Meeting, Nov 6, 2008, "Selective Publication of Antidepressant Trials—Influence on Apparent Efficacy." Part of symposium: "Antidepressants: Are They Effective?"

National

1. American Psychiatric Association 2013, San Francisco, CA; Part of symposium: "Antidepressants in MDD - The efficacy debate", Abstract #1371; ET talk title: "To Be or Not To Be (Effective)...That is NOT the Question".

2. University of Michigan Department of Psychiatry Grand Rounds, March 13, 2013. Topic: Publication bias and psychiatric drugs.

3. American Psychological Association, San Diego,

California, August 2010, talk: "The Emperor's New Journal Articles on Antidepressant Efficacy (and on Research in General)"; part of symposium entitled "Eat Your Data Raw – Data-Based Medicine Versus Evidence-Based Medicine"

4. APA 2009 – part of a symposium presented at 2009 American Psychiatric Association conference, entitled, "Do we have any effective treatments for depression?"

5. Creighton University Medical Center Distinguished Lecturer Series, Omaha, NE, Sept 3, 2008, "Selective Publication of Antidepressant Trials: Are Drugs as Effective as 'Advertised' in Peer-Reviewed Medical Journals?"

6. New Clinical Drug Evaluation Unit (NCDEU), Phoenix, AZ, May 27, 2008, "Selective Publication of Antidepressant Trials", part of Workshop 5, Part II: Dissemination of Clinical Trials Results: A Necessary Step Toward Personalized Treatment 7. Clinical Trial Registries and Results Databases, conference organized by Center for Business Intelligence (CBI): Arlington, VA, April 2006, "A 'Lost Ark' of Clinical Trial Results— Gathering Dust at the FDA"

8. Grand Rounds, Long Beach VA Medical Center, "From Discovery to Market: An Inside View of the FDA Drug Development Process", Jan 2004

9. NIMH Multicenter Clinical Trials: IND Exemptions. New Clinical Drug Evaluation Unit. Boca Raton, FL; 2000. (Talk given on behalf of FDA, invited by NIMH, meeting sponsors.)

10. Estrogen prescribing varies with season and latitude. American Psychiatric Association. New York; 1996: Symposium 12, Talk C.

Regional and Local

1. 2014 Oregon Society of Health-System Pharmacists (OSHP) Annual Seminar. Reporting bias and drugs: Is what you read the truth, the whole truth, and nothing but the truth? April 27, 2014.

2. 2012 OHSU Medical Scientist Training Program (MSTP; MD-PhD) Program Retreat, September 29, 2012, McMenamins Edgefield, Troutdale, Oregon.

3. Portland Psychological Association, talk: The Earth is Flat, d < 0.5: The Silly Debate About Antidepressant Efficacy, Portland, Oregon, February 17, 2011

4. Pacific Northwest Chapter of the Medical Library Association Annual Meeting, talk: Selective Publication & Drug Efficacy: Don't Believe Everything You (Don't) Read; Portland, Oregon, October 11, 2010

5. Advance Practice Nurses Conference 2010, September 24, 2010. Talk: 'The Debate about Antidepressant Efficacy: Magic Bullets or Worthless Placebos?"; Portland VA Medical Center auditorium.

6. AMSA (American Medical Students Association) Integrity Week, May 6, 2009, Talk title: 'Evidence B(i)ased Medicine: Caveat Emptor (Caveat Lector)

7. Bioethics Study Group presentation, March 2009. Transparency or Translucency? Seeing Through the Emperor's Clothes of Evidence B(i)ased Medicine.

8. Lewis & Clark Graduate School of Education and Counseling, Center for Continuing Studies, Annual Continuing Education for Mental Health Therapists, January 30, 2009. Talk title: "Selective Publication of Antidepressant Trials: Are These Drugs as Effective as 'Advertised' in the Peer-Reviewed Literature?"

9. Oregon Psychiatric Association, Ashland, OR, Sept 20, 2008, "Selective Publication of Antidepressant Trials: How Well Do These Drugs Really Work?"

10. Department of Medical Informatics & Clinical Epidemiology, DMICE Informatics Conference, OHSU, Thursday, May 22, 2008, "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy"

11. Drug Effectiveness Review Project, 2008 Spring Governance Meeting, Portland, OR, May 2, 2008, "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy"

12. 19th Annual Kinsman Conference, April 16, 2008, Workshop B-1: "Truth telling and suppressed drug research data." Also member of panel: "Panel: Relationship of organization to community"

13. Behavioral Neuroscience Department, OHSU, March 21, 2007: "What does *all* the evidence say about lamotrigine's efficacy for acute bipolar depression?"

14. Oregon Psychiatric Association, Lake Oswego, OR, March 2, 2007, Critical Interpretation of Clinical Trial Data.

15. Reed College, Portland, OR, November 28 and December 1, 2006; presentation to psychology students: "What does all the evidence say about lamotrigine's efficacy for acute bipolar depression?"

16. Conference: Rational Prescribing – A Preferred Alternative to Formularies, Salem Hospital, "Evidence-Based Prescribing for Bipolar Disorder", Oct 2003

17. Providence Hospital, Portland, OR, Medical Grand Rounds (video broadcast throughout Providence system in west coast states), "FDA Regulation of Drug Development", July 2002

V. SERVICE

Membership in Professional Societies:

- 1989 1998 American Psychiatric Association
- 1993 1998 Washington Psychiatric Society
- 1993 1998 Society on Light Treatment and Biological Rhythms

Editorial and Ad Hoc Review Activities: Peer reviewer for journals

- 1. Archives of General Psychiatry
- 2. British Medical Journal (BMJ)
- 3. Cochrane Collaboration, Methodology Review Group
- 4. Drug Information Journal
- 5. JAMA
- 6. Lancet
- 7. New England Journal of Medicine
- 8. Oregon State Drug Review (newsletter)
- 9. Pharmacoepidemiology and Drug Safety
- 10. PLoS Clinical Trials
- 11. PLoS Medicine
- 12. PLoS ONE
- 13. Systematic Reviews
- 14. Trends in Cognitive Sciences
- 15. Trials (a BioMedCentral journal)

Other editorial activity

Editorial board, Drug Information Journal, 5/2002 - 12/2004 Academic editor, PLoS ONE, 5/2007 – present Academic editor, PLoS Clinical Trials (folded into PLoS ONE), 9/2005 - 4/2007

Committees:

International/National

Nordic Cochrane Centre, Advisory Board, 2010 – present Structured Product Labeling Workgroup on electronic indexing, Health Level 7 (international nonprofit), 2012 – present FDA Transparency Task Force, June 2009, testimony provided Institute of Medicine – testimony to panel making recommendations to Congress regarding Comparative Effectiveness Research. March 2009.

Member of Mock FDA Advisory Committee. Clients: Somerset Pharmaceuticals and BristolMyers-Squibb. Purpose: To discuss question of whether or not dietary restrictions should be required for the 20 mg dose of Emsam (transdermal patch, selegiline (MAOI)). Mock meeting October 14, 2005 in preparation for actual meeting October 26, 2005. Briefing materials for meeting available at:

http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4186b2_index%20with%20disclaimer.htm

Institutional

7/2004 – 12/2004Placebo Taskforce, member, PVAMC12/2003 - 12/2006Institutional Review Board (IRB), MemberIRB#2 Portland VAMCResearch and Development Committee,2/2002 - 12/2004Research and Development Committee,member, PVAMCAntidepressant Cost Reduction Workgroup,10/2001 - 10/2002Antidepressant Cost Reduction Workgroup,member, PVAMCExecutive Secretary, Intramural Review80ard (IRB), NIMH Intramural Program, Bethesda, MD

Departmental

2012 – 2013 Portland VAMC QTc Workgroup, Mental Health Service,

Community Service:

Lincoln High School, Portland; SPARK lecture (Science, Policy, and Research Knowledge), February 8, 2006, Selective Publication of the Medical Literature.

Clinical Responsibilities (since last promotion):

Staff Psychiatrist, Outpatient Clinic, Portland VA Medical Center, March 2001 - present. Current panel size = ~500 unique veterans, + expected 3 intakes per week. Annual performance report overall rating for past 4 fiscal years (chronological order): high satisfactory, high satisfactory, outstanding, outstanding.

VI. TEACHING

Direct Teaching (most items refer to multiple teaching encounters)

Evidence-Based Medicine Course for psychiatry residents. Fall 2007 to present. 15 face-to-face teaching hours per year plus prep time. Course director. Co-teachers: ^{(b) (6)} and OHSU reference librarians. Principles of Clinical Medicine (PCM): One of 3 panelists on conflict of interest in medicine. October 14, 2014.

Scientific Resource Center (SRC): Webinars given to Evidence-based Practice Centers (EPCs) in the US:

(1) July 21, 2014: Peer-Reviewed Literature: Caveat Lector. The Problem of Outcome Reporting Bias. Shared hour-long presentation with

(2) August 13, 2014: How to access and process FDA drug approval packages for use in research. Shared hour-long presentation with $^{(6)}$

(3) January 28, 2015: Searching for Published and Unpublished Trial Data on FDA Website. Hour-long webinar presented to EPC librarians.

OHSU 3rd MS-3 Didactics. Mood Disorders: October 2001 to December 2011. Bipolar Disorder: January 2012 to present.

Most recent (July 2012 – December 2013) clinical supervision of group of 3 psychiatry residents in Portland VA outpatient mental health clinic. Clinical supervision (cumulative 2001-June 2012) of individual trainees:

13 OHSU psychiatry residents, 3 pharmacy residents, 2 Mood Disorders Fellows.

FDA Regulation of Drug Development: 1st year medical students, OHSU, Pharmacology core curriculum, spring 2002-2008. Varied from 1 to 2 (consecutive) hours annually.

How the FDA Communicates with Physicians: 1st year medical students, OHSU, Pharmacology core curriculum, spring 2009-present.

Neuroscience and Behavior Course, OHSU second year med students – three 1-hr seminars annually from spring 2004-2010 covering

schizophrenia, mood disorders, and anxiety disorders

MIRECC (Mental Illness Research, Educational, and Clinical Center) 2/03.

Human Investigations Program, OHSU – one lecture annually, 2003 to present.

OHSU Family Practice Residents, May 2009, Talk title: "Selective Publication of Antidepressant Trials: How Well Do These Drugs Really Work?"

Tips on Using That Rodney Dangerfield of Medical Books, The PDR,

Grand Rounds, OHSU, 6/04

Statistical vs. Clinical Significance in Clinical Drug Trials: The Tyranny of the P Value in Deciding Whether and How Well our Drugs Really Work, Journal Club, given to Portland VA Mental Health Division, 6/03 An Amateur's Guide to Medline Searching, Journal Club, given to Portland VA Mental Health Division 9/03

Designing, Conducting, and Analyzing a Clinical Drug Trial: Student Research Presentation; Mentored small group of OHSU 1st year medical students as part of pharmacology curriculum ~10 one-hour sessions, 2/03– 4/03

Pharmacokinetics small group, 1st year medical students, 2-hr small group workshop, spring term 2003 to present (except 2010)

Pharmacology small group, Salicylate and acetaminophen overdose, 2-hour small group, spring 2003 – 2005

A patient with bipolar disorder and pathological gambling, Clinical Case Conference, given to Portland VA Mental Health Division, 12/02 Treatment of a rapid cycling bipolar patient using extended bed rest and darkness to stabilize the timing and duration of sleep, Clinical Case Conference, presented to PVAMC Mental Health Division, 10/01. Seasonal Affective Disorder, 1-hr talk to nurse practitioners at Portland

VA, December 2001

Seasonal Affective Disorder, Open Mood Disorders Forum, PVAMC Auditorium (lay audience, veterans + non-veterans)

Curriculum Development

Evidence-Based Medicine Course for psychiatry residents. Course director fall 2012 going forward. Previously co-director with (2007 to spring 2012).

Developed class for veterans with mental health problems, "Medications for Mental Health". Taught class together with pharmacists, September 2004 to December 2005. 15-class series, 3 classes per blocks x 4 blocks (depression, bipolar disorder, schizophrenia, anxiety disorders & insomnia). Course ended due to difficulty sustaining recruitment of veterans.

Mentoring and Advising

Mentored early career^{(b) (6)} on project on publication bias with clinical trials of anti-anxiety medications. To be published in JAMA Psychiatry^{(b) (6)}.

Mentored two medical students (b) (6)

during project on selective publication of antipsychotic trials, resulting in their co-authorship of article in peer-reviewed journal. Two to six hours per week ^{(b) (6)}, followed by less frequent

ad hoc contact.

Mentored medical student on project on selective publication of clinical trials of antihypertensive medications. Eight hours per week x 3 months, summer^{(b) (6)}.

Learner Assessment

For course Evidence Based Medicine for Psychiatry Residents, knowledge assessments conducted before start of course and at completion

Honors and Awards for Education

Regional/National

Distinguished Lecturer, Creighton University Medical Ctr, Omaha, NE, September 3, 2008